CDMO Catalent states that their new manufacturing facility will be used to assist both autologous and allogeneic cell therapy studies.
The facility has a total area of 60,000 square feet.
Catalent Acquires Masthercell to Expand Cell Therapy Options
In the year 2020, Catalent completed the acquisition of Masthercell from Orgenesis. This provided them with more alternatives when it came to cell therapy, including a facility in Gosselies, Belgium, that boasts 10 cleanrooms, 4 development labs, and in-house quality control labs that have the capacity to produce 1,000 batches annually.
Additionally, the company has completed and opened a commercial-scale facility in Gosselies, which provides it with additional space to produce autologous and allogeneic cell therapies beginning with early-stage clinical trials and continuing all the way through production for commercial sale.
The company’s spokesperson did not disclose the amount of money that was invested or the number of new positions that would be created.
Masthercell and two other buildings on the Gosselies campus were purchased by a contract development and manufacturing organization (CDMO) in 2021.
These buildings were formerly occupied by Delphi Genetics and Promethera’s cell therapy manufacturing subsidiary (Hepatic Cell Therapy Support).
This year, Catalent expanded its cell therapy business by purchasing RheinCell Therapeutics, an induced pluripotent stem cell (iPSC) company located in Düsseldorf, Germany, and by adding Erytech’s 30,900-square-foot cell therapy plant located in Princeton, New Jersey.
Both of these acquisitions contributed to the company’s growth.
Catalent Cell & Gene Therapy: End-to-End Services for Breakthrough Medicines
Catalent’s president for BioModalities, Manja Boerman, stated that the company is able to provide “fully integrated cell therapy services” due to the fact that it is able to house its “iPSC expertise” in Düsseldorf, Germany, “process and analytical development” in Gosselies, and “clinical and commercial manufacturing” in Gosselies and Princeton, New Jersey, all under one CGMP umbrella.
Catalent Cell & Gene Therapy provides “integrated plasmid DNA and viral vector services” as one component of the company’s “end-to-end services for development, scale up, and commercial launch of breakthrough medicines.”
In order to maintain “utilization rates at sustainable levels to continue to grow profit and cash flow,” as stated by the CEO Alessandro Maselli, the expansion plans for the Princeton location have been postponed until July 2023.
The company has been made aware of the growth freeze that has been implemented at Princeton, according to a spokeswoman for the company, who also stated that “the Gosselies campus is a strong center of cell therapy excellence for Catalent in Europe and will act as a hub of the growing cell therapy pipeline.”